Aurinia Pharmaceuticals (AUPH) Profit After Tax (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Profit After Tax data on file, last reported at $34.1 million in Q1 2026.

• Quarterly Profit After Tax rose 45.96% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.9 million (up 647.73% YoY) and the FY2025 annual result came in at $287.2 million, up 4822.88% from the prior year.
• Profit After Tax fell to $34.1 million in Q1 2026, from $210.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $210.8 million in Q4 2025 to a low of -$37.6 million in Q1 2022.
• A 5-year average of $8.3 million and a median of -$9.0 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax plunged 49.59% — and 2025, when it surged 14651.15%.
• Tracing AUPH's Profit After Tax over 5 years: stood at -$26.0 million in 2022, then retreated by 3.18% to -$26.9 million in 2023, then surged by 105.32% to $1.4 million in 2024, then surged by 14651.15% to $210.8 million in 2025, then plunged by 83.84% to $34.1 million in 2026.
• The last three Profit After Tax figures came in at $34.1 million (Q1 2026), $210.8 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.